{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:02:13Z","timestamp":1792627333659,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neuroleptic malignant syndrome (NMS) may be induced by atypical antipsychotic drugs (AAPDs) such as aripiprazole, olanzapine, risperidone and quetiapine, either as a single treatment or in combination with other drugs. A case of NMS following the administration of lamotrigine, aripiprazole and quetiapine in a patient with bipolar disorder, and with renal failure caused by toxic lithium levels has not been reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 51-year-old female patient with a 27-year history of bipolar disorder, being treated with lithium, fluoxetine, olanzapine, gabapentine, perazine and biperiden, was admitted to the hospital due to depressed mood and delusions. A urinary tract infection was diagnosed and antibiotic therapy was initiated. After 5\u2009days of treatment her physical state deteriorated and she developed a fever of 38.4\u2009\u00b0C. Her laboratory results revealed a toxic level of lithium (2.34\u2009mmol\/l). Acute renal failure was diagnosed and the lithium was withdrawn. After stabilization of her condition, and despite her antipsychotic treatment, further intensification of delusions and depressed mood were observed. All drugs being taken by the patient were withdrawn and lamotrigine and aripiprazole were initiated. Due to the insufficient effectiveness of aripiprazole treatment and because of problems with sleep, quetiapine was added, however further treatment with this drug combination and an increase of quetiapine to 400\u2009mg\/d eventually caused NMS. Amantadine, lorazepam and bromocriptine were therefore initiated and the patient\u2019s condition improved.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This case report indicates that concurrent use of multiple antipsychotic drugs in combination with mood stabilizers in patients with organic disorders confers an increased risk of NMS development.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-020-02597-x","type":"journal-article","created":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T16:02:21Z","timestamp":1587312141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lamotrigine, quetiapine and aripiprazole-induced neuroleptic malignant syndrome in a patient with renal failure caused by lithium: a case report"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-342X","authenticated-orcid":false,"given":"Anna Maria","family":"Szota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Radajewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Grudzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Araszkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,19]]},"reference":[{"key":"2597_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edition (DSM-5). Author, Washington , DC ed.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2597_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1471-244X-12-214","volume":"12","author":"J Langan","year":"2012","unstructured":"Langan J, Martin D, Shajahan P, Smith DJ. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report. BMC Psychiatry. 2012;12:214.","journal-title":"BMC Psychiatry"},{"issue":"8","key":"2597_CR3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0006-3223(97)00530-1","volume":"44","author":"D Berardi","year":"1998","unstructured":"Berardi D, Amore M, Keck PE Jr, Troia M, Dell\u2019Atti M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998;44(8):748\u201354.","journal-title":"Biol Psychiatry"},{"issue":"3","key":"2597_CR4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2174\/1570159X13999150424113345","volume":"13","author":"L Tse","year":"2015","unstructured":"Tse L, Barr AM, Scarapicchia Vila-Rodriguez F. Neuroleptic malignant syndrome: a review from a clinically Orientes perspective. Curr Neuropharmacol. 2015;13(3):395\u2013406.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"2597_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40268-014-0078-0","volume":"15","author":"MB Murri","year":"2015","unstructured":"Murri MB, Bugliani M, Calcagno P, Respino M, Serafini G, Innamorati M, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs RD. 2015;15(1):45\u201362.","journal-title":"Drugs RD"},{"issue":"2","key":"2597_CR6","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1176\/appi.neuropsych.11040093","volume":"24","author":"E Motomura","year":"2012","unstructured":"Motomura E, Tanii H, Usami A, Ohoyama K, Nakagawa M, Okada M. Lamotrigine-induced neuroleptic malignant syndrome under risperidone treatment: a case report. J Neuropsychiatry Clin Neurosci. 2012;24(2):E38\u20139.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"2597_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/WNF.0b013e318294799a","volume":"36","author":"M Ishioka","year":"2013","unstructured":"Ishioka M, Yasui-Furukori N, Hashimoto K, Sugawara N. Neuroleptic malignant syndrome induced by lamotrigine. Clin Neuropharmacol. 2013;36(4):131\u20132.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"2597_CR8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"key":"2597_CR9","first-page":"20(1)","volume":"4","author":"MR Ware","year":"2018","unstructured":"Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. Prim Care Companion CNS Disord. 2018;4:20(1).","journal-title":"Prim Care Companion CNS Disord"},{"issue":"2","key":"2597_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ncl.2003.12.006","volume":"22","author":"MJ Bhanushali","year":"2004","unstructured":"Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin. 2004;22(2):389\u2013411.","journal-title":"Neurol Clin"},{"key":"2597_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/NDT.S118438","volume":"13","author":"R Oruch","year":"2017","unstructured":"Oruch R, Pryme IF, Engelsen BA, Lund A. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. Neuropsychiatr Dis Treat. 2017;13:161\u201375.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"7","key":"2597_CR12","first-page":"572","volume":"39","author":"JK Joseph","year":"1991","unstructured":"Joseph JK, Thomas K. Lithium toxicity-a risk factor for neuroleptic malignant syndrome. J Assoc Physicians India. 1991;39(7):572\u20133.","journal-title":"J Assoc Physicians India"},{"issue":"6","key":"2597_CR13","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1592\/phco.23.6.811.32179","volume":"23","author":"J Gill","year":"2003","unstructured":"Gill J, Singh H, Nugent K. Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy. 2003;23(6):811\u20135.","journal-title":"Pharmacotherapy."},{"issue":"4","key":"2597_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.5001\/omj.2016.59","volume":"31","author":"V Patil","year":"2016","unstructured":"Patil V, Gupta R, Verma R, Balhara YPS. Neuroleptic malignant syndrome associated with Lithium toxicity. Oman Med J. 2016;31(4):309\u201311.","journal-title":"Oman Med J"},{"issue":"3","key":"2597_CR15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1192\/bjp.bp.116.187989","volume":"210","author":"E Joas","year":"2017","unstructured":"Joas E, Karanti A, Song J, Goodwin GM, Lichtenstein P, Landen M. Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder. Brit J Psych. 2017;210(3):197\u2013202.","journal-title":"Brit J Psych"},{"issue":"1","key":"2597_CR16","first-page":"28","volume":"14","author":"A Mosio\u0142ek","year":"2017","unstructured":"Mosio\u0142ek A, Galanty D. All we need to know about neuroleptic malignant syndrome. Psychiatry. 2017;14(1):28\u201334.","journal-title":"Psychiatry"},{"key":"2597_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/1941875210386491","volume":"1","author":"BD Berman","year":"2011","unstructured":"Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1:41\u20137.","journal-title":"Neurohospitalist"},{"issue":"4","key":"2597_CR18","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11126-013-9264-4","volume":"84","author":"MB Detweiler","year":"2013","unstructured":"Detweiler MB, Sullivan K, Sharma TR, Kim KY, Detweiler JG. Case reports of neuroleptic malignant syndrome in context of quetiapine use. Psychiatr Q. 2013;84(4):523\u201341.","journal-title":"Psychiatr Q"},{"issue":"12","key":"2597_CR19","volume":"12","author":"SJ Nevitt","year":"2017","unstructured":"Nevitt SJ, Sudell M, Weston J, Smith CT, Marson AG. Antiepileptic drug monotherapy for epilepsy: a net-work meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017;12(12):CD011412.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2597_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bdi.12025","volume":"15","author":"LN Yatham","year":"2013","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian network for mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1\u201344.","journal-title":"Bipolar Disord"},{"issue":"3","key":"2597_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-005-0020-9","volume":"181","author":"CH Large","year":"2005","unstructured":"Large CH, Webster EL, Goff DC. The potential role of lamotrigine in schizophrenia. Psychopharmacology. 2005;181(3):415\u201336.","journal-title":"Psychopharmacology"},{"issue":"5","key":"2597_CR22","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.pnpbp.2008.03.004","volume":"32","author":"D Muck-Seler","year":"2008","unstructured":"Muck-Seler D, Sagud M, Mustapic M, Nadic G, Babic A, Peles AM, et al. The effect of lamotrigine on platelet monoamine oxidase type B activity in patients with bipolar depression. Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1195\u20138.","journal-title":"Neuropsychopharmacol Biol Psychiatry"},{"key":"2597_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1469-8749.2000.tb00713.x","volume":"42","author":"L Samson-Fang","year":"2004","unstructured":"Samson-Fang L, Gooch J, Norlin C. Intrathecal baclofen withdrawal simulating neuroleptic malignant syndrome in a child with cerebral palsy. Dev Med Child Neurol. 2004;42:561\u20135.","journal-title":"Dev Med Child Neurol"},{"key":"2597_CR24","first-page":"370","volume":"656","author":"N Divac","year":"2014","unstructured":"Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation atipsychotics and extrapyramidal side effects. Biomed Rest In. 2014;656:370.","journal-title":"Biomed Rest In"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02597-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02597-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02597-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T23:19:53Z","timestamp":1618787993000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02597-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,19]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2597"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02597-x","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,19]]},"assertion":[{"value":"22 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval and consent to participate are waived.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A written consent from the patient was obtained for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}